These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 19366906)

  • 41. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk.
    Freedman ML; Penney KL; Stram DO; Riley S; McKean-Cowdin R; Le Marchand L; Altshuler D; Haiman CA
    Cancer Res; 2005 Aug; 65(16):7516-22. PubMed ID: 16103107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 haplotype determination in breast cancer.
    Weston A; Pan CF; Ksieski HB; Wallenstein S; Berkowitz GS; Tartter PI; Bleiweiss IJ; Brower ST; Senie RT; Wolff MS
    Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):105-12. PubMed ID: 9037561
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.
    Försti A; Jin Q; Altieri A; Johansson R; Wagner K; Enquist K; Grzybowska E; Pamula J; Pekala W; Hallmans G; Lenner P; Hemminki K
    Breast Cancer Res Treat; 2007 Jan; 101(1):83-93. PubMed ID: 16807673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides.
    Dialyna I; Tzanakakis G; Dolapsakis G; Tsatsakis A
    Toxicol Lett; 2004 Jun; 151(1):267-71. PubMed ID: 15177662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
    Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
    Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
    Naidu R; Yip CH; Taib NA
    Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
    Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
    Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
    Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
    Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women.
    Zheng SL; Zheng W; Chang BL; Shu XO; Cai Q; Yu H; Dai Q; Xu J; Gao YT
    Cancer Res; 2003 Nov; 63(22):7624-9. PubMed ID: 14633679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.
    Langsenlehner U; Renner W; Yazdani-Biuki B; Eder T; Wascher TC; Paulweber B; Clar H; Hofmann G; Samonigg H; Krippl P
    Breast Cancer Res Treat; 2006 May; 97(1):67-72. PubMed ID: 16317580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
    Pepe C; Guidugli L; Sensi E; Aretini P; D'Andrea E; Montagna M; Manoukian S; Ottini L; Radice P; Viel A; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2007 May; 103(1):29-36. PubMed ID: 17151928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FOXP3 germline polymorphisms are not associated with risk of breast cancer.
    Raskin L; Rennert G; Gruber SB
    Cancer Genet Cytogenet; 2009 Apr; 190(1):40-2. PubMed ID: 19264232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
    Bau DT; Fu YP; Chen ST; Cheng TC; Yu JC; Wu PE; Shen CY
    Cancer Res; 2004 Jul; 64(14):5013-9. PubMed ID: 15256476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer.
    Tamimi RM; Hankinson SE; Spiegelman D; Colditz GA; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):989-96. PubMed ID: 15184255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk.
    Long JR; Egan KM; Dunning L; Shu XO; Cai Q; Cai H; Dai Q; Holtzman J; Gao YT; Zheng W
    Pharmacogenet Genomics; 2006 Apr; 16(4):237-43. PubMed ID: 16538170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
    Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estrogen receptor polymorphisms and the risk of endometrial cancer.
    Ashton KA; Proietto A; Otton G; Symonds I; McEvoy M; Attia J; Gilbert M; Hamann U; Scott RJ
    BJOG; 2009 Jul; 116(8):1053-61. PubMed ID: 19438492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymorphisms in three base excision repair genes and breast cancer risk in Thai women.
    Sangrajrang S; Schmezer P; Burkholder I; Waas P; Boffetta P; Brennan P; Bartsch H; Wiangnon S; Popanda O
    Breast Cancer Res Treat; 2008 Sep; 111(2):279-88. PubMed ID: 17922186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
    Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.